These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23805303)

  • 1. Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty.
    Greer AL; Schanzer D
    PLoS One; 2013; 8(6):e67253. PubMed ID: 23805303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can informal social distancing interventions minimize demand for antiviral treatment during a severe pandemic?
    Greer AL
    BMC Public Health; 2013 Jul; 13():669. PubMed ID: 23866760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza.
    Dimitrov NB; Goll S; Hupert N; Pourbohloul B; Meyers LA
    PLoS One; 2011 Jan; 6(1):e16094. PubMed ID: 21283514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice of Antiviral Allocation Scheme for Pandemic Influenza Depends on Strain Transmissibility, Delivery Delay and Stockpile Size.
    Lydeamore M; Bean N; Black AJ; Ross JV
    Bull Math Biol; 2016 Feb; 78(2):293-321. PubMed ID: 26846916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of optimal antiviral stockpile for a novel influenza pandemic.
    Kim S; Bin Seo Y; Lee J; Kim YS; Jung E
    J Infect Public Health; 2022 Jul; 15(7):720-725. PubMed ID: 35667304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-prioritized use of antivirals during an influenza pandemic.
    Merler S; Ajelli M; Rizzo C
    BMC Infect Dis; 2009 Jul; 9():117. PubMed ID: 19638194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
    Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
    PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.
    McVernon J; McCaw JM; Nolan TM
    Aust N Z J Public Health; 2010 Apr; 34(2):113-9. PubMed ID: 23331352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico.
    Gutiérrez-Mendoza LM; Schwartz B; Méndez de Lira Jde J; Wirtz VJ
    Bull World Health Organ; 2012 Oct; 90(10):782-7. PubMed ID: 23109746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.
    Prosper O; Saucedo O; Thompson D; Torres-Garcia G; Wang X; Castillo-Chavez C
    Math Biosci Eng; 2011 Jan; 8(1):141-70. PubMed ID: 21361405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we prepared for the next influenza pandemic? Lessons from modelling different preparedness policies against four pandemic scenarios.
    Panovska-Griffiths J; Grieco L; van Leeuwen E; Baguelin M; Pebody R; Utley M
    J Theor Biol; 2019 Nov; 481():223-232. PubMed ID: 31059716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile.
    Patel TS; Cinti S; Sun D; Li S; Luo R; Wen B; Gallagher BA; Stevenson JG
    Am J Infect Control; 2017 Mar; 45(3):303-305. PubMed ID: 27816215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing tactics for use of the U.S. Antiviral Strategic National Stockpile for Pandemic (H1N1) Influenza, 2009.
    Dimitrov N; Goll S; Hupert N; Pourbohloul B; Meyers LA
    PLoS Curr; 2009 Nov; 1():RRN1127. PubMed ID: 20029665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
    Moss R; McCaw JM; Cheng AC; Hurt AC; McVernon J
    BMC Infect Dis; 2016 Oct; 16(1):552. PubMed ID: 27724915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.
    Venkatesan S; Carias C; Biggerstaff M; Campbell AP; Nguyen-Van-Tam JS; Kahn E; Myles PR; Meltzer MI
    J Public Health (Oxf); 2019 Jun; 41(2):379-390. PubMed ID: 29955851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral resistance and the control of pandemic influenza.
    Lipsitch M; Cohen T; Murray M; Levin BR
    PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs.
    McCaw JM; Wood JG; McCaw CT; McVernon J
    PLoS One; 2008 Jun; 3(6):e2362. PubMed ID: 18523549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.
    Carrasco LR; Lee VJ; Chen MI; Matchar DB; Thompson JP; Cook AR
    J R Soc Interface; 2011 Sep; 8(62):1307-13. PubMed ID: 21296791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic.
    Goldstein E; Miller JC; O'Hagan JJ; Lipsitch M
    Influenza Other Respir Viruses; 2010 Mar; 4(2):101-12. PubMed ID: 20167050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling community-control strategies to protect hospital resources during an influenza pandemic in Ottawa, Canada.
    Saunders-Hastings P; Quinn Hayes B; Smith R; Krewski D
    PLoS One; 2017; 12(6):e0179315. PubMed ID: 28614365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.